Abstract
Background
Monoclonal antibodies (mAbs) have been developed as effective therapeutics for a wide variety of diseases. Delivery of mAbs by gene transfer provides an option for overcoming the difficulties in mAb production and manufacturing processes. However, for the polymeric structure of full-length mAbs, it is important to design an optimal gene transfer system for mAb generation.
Methods
Gutless adenovirus and liver-specific promoter transthyretin (TTR) were combined to deliver bicistronic mAb genes in human hepatic cell lines. In order to optimize the bicistrons for mAb generation, four bicistrons were designed and compared, and the most efficient one was selected. ELISA and Western blot were conducted to evaluate mAb products in the supernatants.
Results
Our data showed that all of four gutless adenoviruses elicited liver-specific mAb production in HepG2 and Hep3B hepatic cell lines. It was observed that the L2AH bicistron construct (comprising an immunoglobulin light-chain cDNA situated 50 of a heavy-chain cDNA, with a foot-and-mouth disease virus 2A cleavage site in the middle, subcloned into the helper-dependent adenovirus plasmid pGL) could induce the highest level expression of mAb (about 5.0 μg/mL in Hep3B) among these four constructs. Importantly, the mAb products by gene transfer methods retained specific antigen-binding activity.
Conclusion
Our studies gave further evidence that it was feasible to produce active full-length mAb in human hepatic cell lines in vitro by a special gene delivery system. Moreover, we developed an optimized bicistron gene transfer system for future gene therapy research, which may also be of use in industrial mAb production.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reichert JM, Rosensweig CJ, Faden LB, et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073–8
Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349–56
Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27: 331–7
Zuber C, Knackmuss S, Rey C, et al. Single chain Fv antibodies directed against the 37 kDa/67 kDa laminin receptor as therapeutic tools in prion diseases. Mol Immunol 2008; 45: 144–51
Marasco WA. Therapeutic antibody gene transfer. Nat Biotechnol 2005; 23: 551–2
Bakker JM, Bleeker WK, Parren PW. Therapeutic antibody gene transfer: an active approach to passive immunity. Mol Ther 2004; 10: 411–6
Fang J, Qian JJ, Yi S, et al. Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol 2005; 23: 584–90
Jiang M, Shi W, Zhang Q, et al. Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 2006; 12: 6179–85
Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12Suppl. 1: S18–27
Noel D, Pelegrin M, Marin M, et al. In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells. Hum Gene Ther 1997; 8: 1219–29
Noel D, Pelegrin M, Kramer S, et al. High in vivo production of a model monoclonal antibody on adenoviral gene transfer. Hum Gene Ther 2002; 13: 1483–93
Lewis AD, Chen R, Montefiori DC, et al. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002; 16: 8769–75
Kojima H, Fujimiya M, Matsumura K, et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med 2003; 9: 596–603
Kim IH, Jozkowicz A, Piedra PA, et al. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2001; 98: 13282–7
Toietta G, Mane VP, Norona WS, et al. Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2005; 102: 3930–5
Abbas N, Ahmad A, Shakoori AR. Overexpression and purification of PreS region of hepatitis B virus antigenic surface protein adr subtype in Escherichia coli. J Biochem Mol Biol 2007; 40: 1002–8
Costa RH, Grayson DR. Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. Nucleic Acids Res 1991; 19: 4139–45
Brooks AR, Harkins RN, Wang P, et al. Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med 2004; 6: 395–404
Zhang QY, Gu J, Su T, et al. Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem Biophys Res Commun 2005; 338(1): 318–24
Wang L, Hernandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology 2004; 126: 278–89
Jostock T, Vanhove M, Brepoels E, et al. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 2004; 289: 65–80
Li J, Menzel C, Meier D, et al. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. J Immunol Methods 2007; 318: 113–24
Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. Embo J 1994; 13: 928–33
Steiner DF. The proprotein convertases. Curr Opin Chem Biol 1998; 2: 31–9
Chinnasamy D, Milsom MD, Shaffer J, et al. Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI [letter]. Virol J 2006; 3: 14
Szymczak AL, Workman CJ, Wang Y, et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 589–94
Holst J, Vignali KM, Burton AR, et al. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat Methods 2006; 3: 191–7
Yang S, Cohen CJ, Peng PD, et al. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 2008; 15: 1411–23
Ryan MD, King AM, Thomas GP. Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol 1991; 72 (Pt 11): 2727–32
Ng P, Parks RJ, Graham FL. Preparation of helper-dependent adenoviral vectors. Methods Mol Med 2002; 69: 371–88
Fang J, Yi S, Simmons A, et al. An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther 2007; 15: 1153–9
Bianchi AA, McGrew JT. High-level expression of full-length antibodies using trans-complementing expression vectors. Biotechnol Bioeng 2003; 84: 439–44
Schlatter S, Stansfield SH, Dinnis DM, et al. On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog 2005; 21: 122–33
Donnelly ML, Luke G, Mehrotra A, et al. Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol 2001; 82: 1013–25
Acknowledgments
This work was supported by the 973 Project (2004CB518804), the 863 Project (2006AA02Z126) and Zhejiang Province Grant (No. 2006C23006).
The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yin, Y., Lin, F., Zhuang, Q. et al. Generation of Full-Length Functional Antibody against PreS2 of Hepatitis B Virus in Hepatic Cells In Vitro from Bicistrons Mediated by Gutless Adenovirus. BioDrugs 23, 391–397 (2009). https://doi.org/10.2165/11316940-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11316940-000000000-00000